Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HNC364 in Healthy Subjects
NCT05523570Phase 1Completed
- Sponsor
- Guangzhou Henovcom Bioscience Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of HNC364 in Parkinson's disease (PD) (4 arms), sponsored by Guangzhou Henovcom Bioscience Co., Ltd. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events. Started Aug 2022; status: completed.
02
Drugs
HNC364
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05523570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523570.